Protein therapeutics, commonly known as monoclonal antibodies or mAbs, have emerged as the most marketed biologic drug within pharmaceutical companies.
Organic synthesis transformed the biopharmaceuticals industry by allowing companies to produce any molecule to deploy in nearly all therapeutic areas.
Chiral SMB Perspectives with Dr. Olivier Dapremont
A Systematic Approach to Chiral Screening and Method Development
How Nitrosamine Impurities Affect Your Blood Pressure Medicine
Using Core-Shell Technology to Improve HPLC Methods Within USP-Part 3
SEC Method Optimization using the Ph. Eur. for Insulin Fibrils
6 Reasons to CHOOSE Luna® Omega Instead of ACQUITY® BEH
Your Inhaler May Save You From Parkinson's Disease
Chiral Chromatography and the Pharmaceutical Industry
What is USP Chapter 621?
What is Chiral?
